Oncolytic measles virus strains in the treatment of gliomas

Allen, Cory; Paraskevakou, Georgia; Liu, Chunsheng; Iankov, Ianko; Msaouel, Pavlos; Zollman, Paula J.; Myers, Rae; Peng, Kah Whye; Russell, Stephen J.; Galanis, Evanthia

doi:10.1517/14712598.8.2.213

Cited by 63 publications

(28 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results have led to the initiation of a phase I clinical trial in recurrent glioblastoma patients, which is currently ongoing (Allen et al, 2008a;Msaouel et al, 2009a). Although MV-CEA could allow monitoring of viral replication based on detection of the measurable marker CEA in the blood, it does not allow for localization of viral spread.…”

Section: Introductionmentioning

confidence: 99%

Effective Radiovirotherapy for Malignant Gliomas by Using Oncolytic Measles Virus Strains Encoding the Sodium Iodide Symporter (MV-NIS)

et al. 2012

Self Cite

View full text Add to dashboard Cite

Engineered measles virus (MV) strains deriving from the vaccine lineage represent a promising oncolytic platform and are currently being tested in phase I trials. In this study, we have demonstrated that MV strains genetically engineered to express the human sodium iodide symporter (NIS) have significant antitumor activity against glioma lines and orthotopic xenografts; this compares favorably with the MV strain expressing the human carcinoembryonic antigen, which is currently in clinical testing. Expression of NIS protein in infected cells results in effective concentration of radioactive iodine, which allows for in vivo monitoring of localization of MV-NIS infection by measuring uptake of (123)I or (99m)Tc. In addition, radiovirotherapy with MV-NIS followed by (131)I administration resulted in significant increase of MV-NIS antitumor activity as compared with virus alone in both subcutaneous (p=0.0003) and orthotopic (p=0.004) glioblastoma models. In conclusion, MV-NIS-based radiovirotherapy has significant antitumor activity against glioblastoma multiforme and represents a promising candidate for clinical translation.

show abstract

Section: Introductionmentioning

confidence: 99%

Effective Radiovirotherapy for Malignant Gliomas by Using Oncolytic Measles Virus Strains Encoding the Sodium Iodide Symporter (MV-NIS)

et al. 2012

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recently, live attenuated MV Edmonston vaccine strain derivatives have been investigated as potential oncolytic agents for various types of cancer. [5][6][7][8] Three cellular proteins have been identified as MV receptors. Signaling lymphocyte activation molecule (SLAM) is predominantly expressed on cells of the immune system.…”

mentioning

confidence: 99%

Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment

et al. 2012

View full text Add to dashboard Cite

Oncolytic viruses hold much promise as novel therapeutic agents that can be combined with conventional therapeutic modalities. Measles virus (MV) is known to enter cells using the signaling lymphocyte activation molecule (SLAM), which is expressed on cells of the immune system. Although human breast cancer cell lines do not express SLAM, we found that a wild-type MV (HL strain) efficiently infected various breast cancer cell lines, causing cell death. Based on this finding, we used reverse genetics to generate a recombinant MV selectively unable to use SLAM (rMV-SLAMblind). The rMV-SLAMblind lacked infectivity for SLAM-positive lymphoid cells, while retaining oncolytic activity against breast cancer cells. We showed that, unlike the MV vaccine strains, rMV-SLAMblind used PVRL4 (polio virus receptor-related 4) as a receptor to infect breast cancer cells and not the ubiquitously expressed CD46. Consistent with this, rMV-SLAMblind infected CD46-positive primary normal human cells at a much-reduced level, whereas a vaccine strain of the Edmonston lineage (rMV-Edmonston) efficiently infected and killed them. The rMV-SLAMblind showed antitumor activity against human breast cancer xenografts in immunodeficient mice. The oncolytic activity of rMV-SLAMblind was significantly greater than that of rMV-Edmonston. To assess the in vivo safety, three monkeys seronegative for MV were inoculated with rMV-SLAMblind, and no clinical symptoms were documented. On the basis of these results, rMV-SLAMblind could be a promising candidate as a novel oncolytic virus for breast cancer treatment.

show abstract

“…Même si le faible effectif de patients et/ou le . Ainsi, des modifications de la protéine H ont permis sa liaison au récepteur PSCA (prostate stem cell antigen) exprimé sur les cellules cancéreuses prostatiques et pancréa-tiques [14], au prostate-specific membrane antigen (PSMA) surexprimé sur les cellules prostatiques [19], à l'ACE exprimé sur les cellules cancéreuses coliques [15], au CD20 exprimé par les cellules lymphomateuses [16], à une forme mutante (EGFRvIII) du récepteur à l'EGF (epidermal growth factor) ou au récepteur de l'interleukine-13, tous deux surexprimés par les cellules de gliome [17,18]. Ces changements de la spécifi-cité de reconnaissance par le virus des cellules cibles doit permettre d'augmenter la sécurité du traitement.…”

Section: Justification De L'utilisation Du Virus De La Rougeole En Caunclassified

“…Cependant, un cas d'encéphalite aiguë à inclusions a été décrit chez un enfant immunodéprimé ayant reçu une dose vaccinale de virus modification de ce modèle a été créée : une séquence de type interleukine 13 a été introduite à l'extrémité carboxy-terminale de la protéine H ; comme les cellules de glioblastome surexpriment le récepteur à l'interleukine 13, le virus se liera de façon préférentielle aux cellules tumorales. Dans ce modèle, les animaux traités avec ce virus modifié n'ont présenté aucun signe de toxicité [18].…”

Section: Association Virus Et Traitement Immunosuppresseurunclassified